Identification of resistance mechanisms to EGFR treatment in the real world using a clinicogenomic database Published April 2018 Citation Singal, G, Li, G, Agarwala, V, Kaushik, G, O’Connell, C, Alpha-CobbG, Caron, T, Bourque, D, Guria, A, Frank, S, Frampton, G, Carson, K, Abernethy, A.P., Miller, V.A. . AACR Annual Meeting. . https://4076230.fs1.hubspotusercontent-na1.net/hubfs/4076230/flatiron-com-pdf/AACR-2018-FH-FMI-CGDB-Poster-180411.pdf Authors: Sources:American Association for Cancer Research Annual Meeting Share Posted inPublicationsDrug discovery More publicationsISPORApril 2026Impact of telemedicine encounters on survival outcomes in advanced lung cancer: A time-varying cox analysis using EHR-derived dataParatane D, Adamson B, Zemplenyi APublication summaryPublicationsNon-small cell lung cancerISPORApril 2026Real-world (RW) treatment patterns and outcomes in patients with =2 lines of therapy (LOTS) for recurrent or progressive endometrial cancerBhak R, Iyer NN, Hopkins A, et al.Publication summaryPublicationsTreatment patternsAdvanced endometrial cancerISPORApril 2026From real-world data (RWD) to digital twins: building models for patient-level counterfactual prediction in oncologyGriffith S, Manfredonia J, Ricottone M, et al.Publication summaryPublicationsMachine learningNon-small cell lung cancerArtificial intelligence